Hereditary hypophosphatemic rickets with hypercalciuria Case report
Main Article Content
Abstract
Background: Hypophosphatemic rickets with hypercalciuria (HHRH) is an autosomal recessive disease with an estimated prevalence of 1:250,000 children, characterized by loss of function of the sodium-phosphate cotransporter NPT-2c as well as excessive urinary phosphate excretion with consequent manifestation of rickets, muscle weakness and short stature.
Presentation of the case: We present a 12-year-old patient with a family history of nephrolithiasis, who at 7 years of age debuted with kidney stones and bilateral nephrocalcinosis without the need for surgical intervention. Paraclinical tests revealed low serum phosphorus levels, elevated alkaline phosphatase, vitamin D insufficiency, and increased calciuria. The physical examination revealed a bone age of 11 years, long bone osteopenia, thoracolumbar scoliosis, and pelvic imbalance. Initially, rickets was suspected, however, other findings led to the suspicion of Familial Hypophosphatemic Rickets associated with Hypercalciuria. Genetic studies confirmed the mutation in the SLC34A3 gene. The patient was treated with thiazide diuretics, phosphorus supplements, and vitamin D.
Conclusion: HHRH is a pathology whose estimated prevalence is low in pediatrics; however, timely diagnosis and targeted treatment in pediatric patients translate into improvement in symptoms and, as a consequence, improvement in the children’s quality of life.
Downloads
Article Details

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Creative Commons
License Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
You are free to:
Share - copy and redistribute the material in any medium or format.
Adapt - remix, transform, and build upon the material The licensor cannot revoke these freedoms as long as you follow the license terms.
• Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
• NonCommercial — You may not use the material for commercial purposes.
• ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
• No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
References
(1) Santana Hernández EE, Gertrudis E, Font R. Raquitismo hipofosfatémico. Presentación de un caso Hypophosphatemic rickects. Case Presentation. 2018
(2) Bergwitz C, Miyamoto KI. Hereditary hypophosphatemic rickets with hypercalciuria: pathophysiology, clinical presentation, diagnosis and therapy. Pflug. Arch. Eur. J. Physiol 2019; 471(1):149-63. DOI: 10.1007/s00424-018-2184-2
(3) Cormier C, Koumakis E. Métodos de exploración del metabolismo del calcio y el fosfato. EMC - Aparato Locomotor 2021; 54(1):1-17
(4) Areses-Trapote R, López-García JA, Ubetagoyena-Arrieta M, Eizaguirre A, Sáez-Villaverde R. Raquitismo hipofosfatémico hereditario con hipercalciuria: a propósito de un caso. Nefrología 2012;32(4):529-34
(5) Barilari C. Raquitismo hipofosfatémico hereditario con hipercalciuria. Rev. Nefrol. Dial. Traspl. 2015; 35(3):168-71
(6) Colazo JM, Reasoner SA, Holt G, Faugere MCM, Dahir KM. Hereditary Hypophosphatemic Rickets with Hypercalciuria (HHRH) Presenting with Genu Valgum Deformity: Treatment with Phosphate Supplementation and Surgical Correction. Case Rep Endocrinol 2020; 1047327. DOI: 10.1155/2020/1047327
(7) Tavana N, Thilakavathy K, Kennerson ML, Ting TH. Genetic basis of hereditary hypophosphataemic rickets and phenotype presentation in children and adults. Endokrynol. Pol. 2021; 72:366-94
(8) Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet 2019; 393(10189):2416-27